SIGA Stock Cash Flow Statements

SIGA Technologies Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

SIGA Technologies Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31

cash flows from operating activities:
net income										-918,255	-811,794	33,040,588	2,037,061	-361,049				-812,105							-3,162,492	1,629,777	52,390,934	388,050,414	-7,051,264	-11,582,256	-10,302,723	-9,816,377	-7,501,438	-8,614,946	-10,439,900	-9,243,642	-9,565,851	-10,448,567	-20,094,048	-5,630,520	-6,573,437	-7,153,319	-19,056,255	-240,076,761	-2,948,263	-3,381,859	-3,188,310	-2,940,393	-4,346,557	-4,052,893	-5,756,989	210,513	23,841,927	-4,701,275	-13,577,129	-5,637,131	-4,571,621	-4,409,458					-1,571,456	-3,028,881	-3,140,736	-858,304
adjustments to reconcile net income to net cash from operating activities:
depreciation and other amortization	138,986	135,308	130,729	128,382	140,839	138,471	137,591	135,924	133,657	131,121	131,203	130,203	128,711	127,526	128,701	128,833	134,008	130,826	132,678	129,467	134,506	133,163	131,457	130,251	127,565	137,724	20,991	14,710	4,139	29,790	26,977	29,375	39,662	36,175	43,571	42,660	43,592	44,452	48,213	52,290	68,076	78,778	83,524	87,233	89,698	91,106	111,650	98,735	105,619	103,354	103,020	117,954	182,132	165,182
stock-based compensation	1,234,439	902,280	764,070	813,774	932,287	1,130,010	462,469	459,823	721,440	408,730	686,417	328,685	395,454	368,754	308,489	243,503	467,405	246,412	387,576	380,823	323,533	259,016	396,614	761,096	547,390	408,894	406,898	1,176,558	362,361	327,360	327,360	400,179	285,898	87,594	253,875	153,230	172,571	195,865	348,733	352,282	381,299	491,724	598,469	531,547	606,595	698,851
write down of inventory			0	0			16,298	44,390			33,026	10,706	22,269	135,471																	0	0
deferred income taxes	7,165,351	-277,850		-492,840	-600,257	36,450		-305,833	-857,933	-483,425		-1,144,072	995,327	-1,612,534		-220,813	-158,879	-28,541		4,699,489	5,121,097	-2,153,695										-807	0	21,190	4,177	4,801	-807	12,252	7,560	3,916	4,611	5,016	3,566	57,741,011	-1,628,027	-2,547,479	-1,784,017	-2,470,346	-1,660,720	-1,932,719	-1,629,602	-1,526,848	-32,908,415	12,887
deferred iv tpoxx® revenue			-3,398,640	0
changes in assets and liabilities:
accounts receivable	699,108	13,980,644	-9,077,119	-3,134,577	9,172,747	3,003,771	-13,080,892	-2,023,172	6,289,817	33,090,256	9,518,598	-35,327,436	-14,259,222	78,311,550	-79,827,626	3,383,311	-3,204,876	-660,996	37,058,445	-3,787,047	-34,926,019	2,482,354	-950,295	910,515	-28,262	-2,140,821	-419,595	589,419	-865,277	645,730	-1,189,941	1,156,815	3,109,650	-1,724,261	35,592,707	-4,258,343	-33,485,580	2,673,576	-2,697,498	-210,018	13,503,103	-13,780,685	77,429	173,648	-132,289	371,603	-1,031,257	-191,320	145,350	-1,027,177	-928,809	100,346	-563,399	1,756,903	-1,640,908	2,084,111	-136,412	-903,074			-712,337,327,915	712,336,434,558	-948,531	361,757	-820,903	434,558
inventory	22,971,672	-9,496,799	12,666,560	-6,360,020	7,523,995	1,512,118	715,594	-14,497,515	-8,437,867	-3,304,697	-8,044,770	-14,840,670	-176,150	3,097,407	10,092,445	-9,990,997	179,773	-144,852	-9,517,987	3,259,454	2,335,028	-4,086,487	-5,721,693	-1,540,675	-373,409	891,133					0	12,433,559	3,166,747	7,090,409	-8,458,445	11,180,374	-6,090,032	-10,394,773	-11,355,140	7,678,540	6,045,347	4,228,642	-917,566	-1,281,304	229,938	3,439,804	-284,585	-8,497,367	-7,936,775	-923,195
prepaid expenses and other assets	481,939	-175,802	2,401,287	-494,213	-2,737,895	239,518	-1,578,335	-323,243	321,762	-1,431,530	-1,342,339	2,106,318	-833,775	241,607	188,947	-762,093	202,714	419,395	-795,719	291,131	1,181,431	22,259	-2,903,348
accounts payable, accrued expenses and other liabilities	-9,636,513	10,409,997	-2,079,717	766,720	-957,798	-3,468,684	2,698,023	1,233,907	1,075,985	-3,011,077	1,151,935	-668,540	3,464,393	-1,881,714	-7,236,892	11,043,055	510,943	-3,330,241	-2,679,117	4,896,426	-2,797,009	-1,624,681	1,634,164
income tax payable	4,165,573	-8,007,679	7,892,552	45,358	-2,621,233	-18,987,210	21,636,468	42,610	-1,323,489	25,639	-7,813,481	8,488,534	-174,152	-18,398,271
net cash provided by/(used in) operating activities	63,084,829	7,061,876										-4,781,371	-2,207,753	56,706,411
cash flows from investing activities:
capital expenditures	-1	-24,893	-17,838	-22,427			0	0							-26,196	0	-10,700	-13,724	0	0	0	-15,501	-2	-20,144	3	-8,951	-74,401	0			-45,882	-14,916			-12,930	1	-2,523	-8,475	-45,787				-2,152	0	-11,710	-14,184	-324,780	-18,266	-61,791	-183,398	-123,477	-18,164	-51,873	-43,509	-16,948	193,909	-558,591	-168,314					-50,883	-122,871	-8,462	-158,006
free cash flows							79,031,730	-5,099,370													-9,088,672	3,306,946			-4,347,809	428	-3,665,600				-5,604,278	-5,067,811			-24,690,969	-56,235,067	-26,038,994	-8,649,678	-16,562,716				-4,468,711	10,118,315	-8,079,710	16,578,580	4,435,562	-12,268,735	-6,307,744	-6,670,144	37,106,095	-2,916,859	-4,503,758	-4,348,465	-3,447,868	-2,465,700	-2,108,935	-3,352,825					-852,664	-2,519,379	-2,398,013	-1,768,052
cash from investing activities	-1	-24,893	-17,838	-22,427			0	0
cash flows from financing activities:
payment of employee tax obligations for common stock tendered	-26,113	-166,193	-161,756	-282,600	-196,559	-158,980	0	0			0	0	0	-12,533	0	-160,557	0	-13,361	-7	-174,263	0	-9,746	-976,769	-143,220	0	-56,590	-2,366,150	-1,695,963			-398,015	0	0	-193,052
payment of dividend			0	8,468			0	0			3,919	0
cash from financing activities	-42,892,796	-166,193	-161,756	-274,132	-42,870,071	-158,980	0	0	-35,865,366	-7,557,057	-2,852,708	0	-36,521,235	-6,585,316
net increase/(decrease) in cash and cash equivalents	20,192,032	6,870,790
cash and cash equivalents at the beginning of period	0	155,400,262	0	0	0	150,145,844	0	0	0	98,790,622
cash and cash equivalents at end of period	20,192,032	162,271,052	56,130,506	-7,680,030	-36,918,862	143,868,648	79,031,730	-5,099,370	-39,467,199	115,680,683	-10,958,933	-4,781,371	-38,728,988	153,259,914		-5,666,588	-8,041,482	106,527,495													-5,940,292	-5,067,811	762,362	30,103,574	8,209,036	-57,529,568	-26,038,994	104,061,350	-16,578,247	13,633,125	20,110,531	95,545,619	-4,968,713	5,653,315	-8,037,743	107,067,070	9,345,562	-12,260,848	-7,655,700	42,588,476	36,846,972	7,409,594	1,164,449	3,835,915	620,276	-828,226	-1,968,024	8,508,027	-14,422,548,461,442	14,422,561,349,484	-15,636,603,481,902	15,636,605,090,173	-636,236	-2,465,059	332,641	5,090,173
supplemental disclosure of non-cash financing activities:
non-cash lease right-of-use asset and associated liability			0	0
issuance of common stock			0	0	0	417,000
net (loss)/income		-408,223						-393,066								-3,113,357						-8,897,529
adjustments to reconcile net (loss)/income to net cash from operating activities:
gain on change in fair value of warrant liability												0	-49,559	-351,104
deferred income taxes provision
net cash from operating activities							79,031,730	-5,099,370	-3,580,147	24,447,118											-9,088,672	3,322,447			-4,347,812	9,379	-3,591,199				-5,558,396	-5,052,895	858,191	1,594,802	-24,678,039	-56,235,068	-26,036,471	-8,641,203	-16,516,929	13,696,291	20,098,331	-6,168,310	-4,466,559	10,118,315	-8,068,000	16,592,764	4,760,342	-12,250,469	-6,245,953	-6,486,746	37,229,572	-2,898,695	-4,451,885	-4,304,956	-3,430,920	-2,659,609	-1,550,344	-3,184,511					-801,781	-2,396,508	-2,389,551	-1,610,046
repurchase of common stock							0	0	-3,515,454	-7,557,057	-2,856,627	0	-3,576,921	-6,572,783	-5,756,972	-7,134,689	-6,600,510	-6,529,348	-6,719,657	-5,567,119	-15,222,795	-993,375																													-259,720	0
supplemental disclosure of cash flows information:
conversion of warrant to common stock											0	0
issuance of common stock upon cashless exercise							0																0	0	0	118,500
cash income taxes paid
net income/				1,343,945	1,832,616	10,277,340														24,187,955
adjustments to reconcile net income/(loss) to net cash from operating activities:
net cash (used in)/provided by operating activities				-7,383,471	5,953,394	-6,118,216												-4,806,312
net decrease in cash and cash equivalents				-7,680,030																									-5,228,104	-8,561,703																			-7,655,700	-6,668,454			1,164,449	-2,496,138										-2,465,059	332,641	-1,742,117
net (decrease)/increase in cash and cash equivalents						-6,277,196		-5,099,370
deferred income taxes benefit																							-1,351,942					-25,510,838	-19	-9,758
deferred revenue								10,526,805	853,408	-59,644	451,479	3,094,313	6,241,890	-2,971,232	177,306	-67,150	81,002	292,591	-3,357,020	-3,992,779	-2,970,984	11,303,389	-1,813,666	-1,252,074	-73,693	1,277,828			-723,024	169,269	1,449,710	966,967	277,080	8,719,141	360,331	78,830,167	32,819,211	215,825	163,577	21,354,828	220,211,005	13,447,162	81,799	-188,081,857	298,477	25,561,191	13,448,118	611,293	265,573	1,725,926				-22,610	-22,111	-388,053	-61,284	-908,023	251,165	-10,051	-8,840	35,360
net increase in cash and cash equivalents										16,890,061																	72,316,276						762,362	1,401,750	8,209,036	-57,529,568	-26,038,994	-8,649,678	-16,578,247	13,633,125	20,110,531	-4,168,310	-4,968,713	5,653,315	-8,037,743	15,757,316	9,345,562				36,846,972				620,276			-5,988,286
(gain) loss on change in fair value of warrant liability
loss on extinguishment of term loan																			0	0	0	4,981,461
non-cash interest expense																			0	0	0	887,132	1,133,559	1,133,559	1,121,237	1,108,916	1,133,561	1,133,559	1,121,237	1,108,916	1,133,559	1,133,558	1,121,238	1,108,916					0	0	0	10,052	5,863	7,162	8,444	9,706
repayment of term loan																			0	0	0	-85,913,459
cash, cash equivalents and restricted cash at the beginning of period													0	103,138,819	0	0	0	117,890,240	0	0	0	160,986,934	0	0	0	180,396,910	0	0	0	37,101,586
net increase/(decrease) in cash, cash equivalents and restricted cash													-38,728,988	50,121,095
cash, cash equivalents and restricted cash at end of period																			39,226,714	25,597,693	-24,311,467	77,377,300	-15,241,071	235,066	-4,347,809	180,340,748	72,316,276	84,768,855	-5,228,104	28,539,883
cash income taxes paid (refund)
(gain)/loss on change in fair value of warrant liability																1,066,522	-442,269	-918,801
loss on inventory																-82,156
net cash from investing activities																0	-10,700	-13,724	0	0	0	-15,501	-2	-20,144	3	-8,951					-45,882	-14,916			1,199,661	1	-2,523	-8,475	-45,787	-63,166	0	4,000,000	-2,152	-3,965,000	522,897	-14,184	-324,780	-18,266	-1,409,747	-183,398	-135,266	9,981,836	4,949,580	-37,890	-1,262,230	-4,800,990	-555,030	-3,917,616					-50,883	-122,871	-8,462	-158,006
net cash from financing activities																-7,295,246	-6,600,510	-6,542,709	-6,719,664	-5,741,382	-15,222,795	-86,916,580	-976,769	-143,220	0	-56,590					-336,014	0			31,687,414						12,200	-2,000,000	-500,002	-500,000	-492,640	-821,264	4,910,000	7,887	0	1,690	-247,334	326,453	666,754	1,846,708	5,313,426	6,632,373	137,350	1,113,841	-57,746,056,825,257	57,746,079,006,823	-129,406,221,849	129,410,025,935	216,428	54,320	2,730,654	25,935
net decrease in cash, cash equivalents and restricted cash																-5,666,588	-8,041,482	-11,362,745		25,597,693					-4,347,809	-56,162
net realization of deferred revenue and costs due to fda approval																											0
gain on sale of priority review voucher
net proceeds from sale of priority review voucher
net proceeds from exercise of stock options																											9,200
supplemental disclosure of cash inflows information:
loss/(gain) on change in fair value of warrant liability																				1,274,156	1,619,587	16,065
supplemental disclosure of non-cash activities:
conversion of warrants to common stock																								0	0	1,172,801	0
net (decrease)/increase in cash, cash equivalents and restricted cash																						-83,609,634
lease termination																															0
deferred costs																													-130,088	184,864	148,910	-13,551,212	-4,151,473	-6,389,282	1,739,713	-18,200,386	-3,152,969	-99,207	1,372,567	-8,349,334	-7,669,539	-5,429,248	-51,433	-2,711,858	-920,827	-6,593,554	-443,723	-460,140	-430,979	-1,256,620
buy back of stock options																																0
cash income taxes (refund) paid
(decrease)/increase in fair value of warrant liability																								-981,923	-656,523	-3,136,265
net realization of deferred revenue and costs due to fda approval of oral tpoxx®
deferred income taxes provision benefit
prepaid expenses and other current assets																									371,198	442,484	-3,182,690	255,008	585,633	119,433	-927,603	-520,750	360,357	22,423	1,504,879	-335,013	-1,571,676	71,367	264,498	264,649	-741,974	442,093	-265,440	622,616	-586,131	-7,179
other assets																									63,001	65,916	36,319								-1,266,509	-519							24,721	7,919	-8,967	19,513	-555,920	0	0	7,501	-163,669	-90,140			-5,935	-6,048	43,587	-7,501					-1,144	-12,237	-2,500	-6,209
accounts payable, accrued expenses and other current liabilities																									-910,437	-937,637	2,655,982	-179,554	1,937,946	-2,792,043	-128,198	-1,190,422	1,365,572	-1,894,379	-563,022	-5,508,870	-311,182	6,205,732			465,634	2,087,773	3,261,921	-3,598,679	-2,619,543	-902,264	-1,323,003	1,285,498	7,372,790	215,704
other liabilities																									-212,570	-244,248	359,160	199,095	-69,273	-66,122	-4,153	-189,835	12,499	-22,165	-21,057	-21,057	-21,057	-21,057			-18,277	-15,487				-10,570	4,323	4,798	4,798	4,798	63,887	62,774
deferred income taxes provision/																										505,678
loss on change in fair value of warrant liability																															4,111,129	295,771
deferred income taxes (benefit)/provision
non-cash backstop fee
liabilities subject to compromise																																			46,900,000	0	-209,875,502	2,903,332	14,344,221	-15,189	-206,397,208	379	12,095,654
return of collateral for surety bond
net proceeds from equity rights offering - net of offering costs
proceeds from term loan escrow release
debt issue costs
portion of term loan paid directly to pharmathene by the lender in satisfaction of the pharmathene claim; such liability is part of the liabilities subject to compromise line item
cash interest paid on pharmathene liability
fair value of warrant, at issuance date, in connection with loan agreement and recorded as warrant liability
increase in fair value of warrant liability																												2,328,674	-360,285	3,303,114				626,209
net cash (used in) investing activities																												0
net cash (used in) financing activities																												-1,443,284
adjustments to reconcile net income to net cash (used in) operating activities:
net cash (used in) operating activities																													-5,187,914	-8,561,703
loss on disposal of assets
interest expense on term loan-paid with restricted cash
restricted cash																																							0	0	0	4,000,000	0
net proceeds from exercise of warrants and options																															62,001								0	0			0	0	7,360	94,675	0	7,887	0	1,690	12,386	326,453	1,760,690	1,846,708	10,813,426	1,132,373	137,350	1,113,841	-32,746,075,549,704	32,746,079,165,850	-129,406,221,849	129,410,025,935	216,428	107,428	2,836,573	25,935
net proceeds from equity rights offering-net of offering costs
buy-back of stock options
debt issuance costs
repayment of long-term debt																																							0	0	0	-2,000,000	-500,000	-500,000	-500,000	-500,001
excess tax benefit from stock-based compensation
net decrease/increase in cash and cash equivalents
cash and cash equivalents at beginning of period																															0	0	0	28,701,824	0	0	0	112,711,028	0	0	0	99,713,929	0	0	0	91,309,754	0	0	0	49,256,930	0	0	0	6,332,053	0	0	0	14,496,313	-23,215,194,510,771	23,215,194,510,771	-23,215,194,510,771	23,215,196,832,290	0	0	0	6,832,290
cash interest paid on term loan from restricted cash																															2,655,073	2,574,863	2,530,755	2,527,778
interest expense on term loan - paid with restricted cash																																2,574,863	2,530,755	2,527,778
pharmathene liability																																				-110,000,000
payments associated with loan agreement and rights offering
net cash used by financing activities																																		-193,052
gain on sale of assets																																											0	-23,771
proceeds from sale of assets																																											0	35,000
supplemental disclosures of cash flows information:
reclass of common stock warrant liability to additional paid-in capital upon warrant exercise
adjustments to reconcile net income to net cash from in operating activities:
write-off of leasehold improvements																																								0
increase in fair value of warrant liabilities
fair value of warrants, at issuance date, in connection with loan agreement and recorded as warrant liabilities
increase in fair value of warrants																																											0	-11,532	-145,788	-156,105	-462,735	15,032	-325,012	436,813	-402,043	-4,726,054	-2,039,851	-1,762,958	9,804,095
payment of common stock tendered for employee tax obligations																																											-2	0	0	-415,938
proceeds from the issuance of long-term debt
change in excess tax benefit from stock-based compensation
decrease in fair value of warrants
reorganization items																																										-581,190	-366,531
collateral for surety bond																																															0	0
proceeds from maturity of short term investments																																																			0	10,000,000	15,000,000	15,000,000	13,750,000
purchases of short term investments																																																			-11,789	0	-9,998,547	-14,994,381	-14,995,282	-13,744,899	-8,746,439	-3,749,302
stock based compensation																																															395,745	426,887	641,777	315,106	1,710,731	2,494,097	7,077,692	1,181,252	196,882	218,846	823,565	244,662	-1,418,616,549,343	1,418,617,580,465	-384,765,036,719	384,766,147,369	350,178	184,393	359,353	147,369
prepaid expenses																																															-125,944	-133,146	-81,817	-103,344	-2,807	11,084	-22,034	25,876	12,470	224,416	2,547	976,622					-54,913	-1,252,900	36,616	8,705
proceeds from the issuance of debt
adjustments to reconcile net income to net cash from operating activities
accrued interest on short-term investments																																																				-150	-1,753	-5,819
proceeds from issuance of securities
adjustments to reconcile net income to net cash from operating
activities
accounts payable and accrued expenses																																																						-954,394	1,464,372	-2,543,642	564,039	389,302	292,855	92,758			971,340	323,719	174,286	-570,446
reclass of common stock warrant liability to additional paid-in capital
upon exercise																																																				0	0	970,816
accounts payable, accrued expenses, and other current liabilities
depreciation																																																							162,169	162,423	172,312	128,439	-354,245,867,947	354,246,110,567	-112,822,087,948	112,822,320,419	116,844	114,913	-92,294	320,419
deferred transaction costs																																																															0	-53,108
adjustments to reconcile net income to net
cash from operating activities:
increase in fair value of rights and warrants																																																									1,548,927	1,368,516			7,763,035	3,944,735
proceeds from short term investments
other current assets																																																										-63,996
amortization of intangible assets
net proceeds from the sale of 2,725,339 shares
of common stock
repayment of notes payable
cash paid for interest on notes payable
decrease in fair value of rights and warrants
proceeds from issuance of securites under letter agreement
increase in fair market value of rights and warrants																																																															-966,699	912,728	1,096,627	-1,086,138
non-cash consulting expense
net proceeds from issuance of common stock and derivatives
proceeds from issuance of notes payable
net proceeds from exercise of common stock rights
non-cash supplemental information:
conversion of preferred stock to common stock
cashless exercise of warrants to purchase common stock
loss on impairment of investments
loss on write-off of prepaid investments

We provide you with 20 years of cash flow statements for SIGA Technologies stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of SIGA Technologies stock. Explore the full financial landscape of SIGA Technologies stock with our expertly curated income statements.

The information provided in this report about SIGA Technologies stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.